INNOVIVA, INC. (INVA) Spending and interest coverage
- R&D / revenue · 12 months: Value 6.51%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 2.77%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value 8.92×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 6.51% | Research and development expense / revenue. Period ending 2026-06-30. $28.66M ÷ $440.00M × 100 ≈ 6.51% |
| Stock-based compensation / revenue · 12 months | 2.77% | Share-based compensation / revenue. Period ending 2026-06-30. $12.19M ÷ $440.00M × 100 ≈ 2.77% |
| Interest coverage · 12 months | 8.92× | Operating income ÷ reported interest expense. $162.57M ÷ $18.23M ≈ 8.92× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 28.66M USD | Research and Development Expense |
| Revenue | 440.00M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 12.19M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 162.57M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 18.23M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $28.66M | $440.00M | $12.19M | $162.57M | $18.23M | 6.51% | 2.77% | 8.92× | Reported |
| 2026-03-31 | $31.45M | $420.69M | $9.87M | $160.47M | $17.42M | 7.48% | 2.35% | 9.21× | Reported |
| 2025-12-31 | $30.60M | $411.33M | $9.45M | $163.75M | $16.70M | 7.44% | 2.30% | 9.81× | Reported |
| 2025-09-30 | $29.71M | $388.52M | $8.62M | (m) | $18.14M | 7.65% | 2.22% | (m) | Reported |
| 2025-06-30 | $19.59M | $370.23M | $7.84M | (m) | $19.93M | 5.29% | 2.12% | (m) | Reported |
| 2025-03-31 | $14.17M | $369.84M | $7.07M | (m) | $21.07M | 3.83% | 1.91% | (m) | Reported |
| 2024-12-31 | $13.65M | $358.71M | $6.37M | (m) | $22.21M | 3.81% | 1.78% | (m) | Reported |
| 2024-09-30 | $12.35M | $352.75M | $5.98M | (m) | $23.41M | 3.50% | 1.69% | (m) | Reported |
| 2024-06-30 | $12.78M | $330.50M | $5.82M | (m) | $22.00M | 3.87% | 1.76% | (m) | Reported |
| 2024-03-31 | $25.21M | $311.59M | $5.69M | (m) | $20.58M | 8.09% | 1.83% | (m) | Reported |
| 2023-12-31 | $33.92M | $310.46M | $5.84M | (m) | $19.16M | 10.93% | 1.88% | (m) | Reported |
| 2023-09-30 | $41.55M | $290.43M | $5.89M | (m) | $17.23M | 14.31% | 2.03% | (m) | Reported |
| 2023-06-30 | $49.29M | $290.42M | $8.16M | (m) | $17.93M | 16.97% | 2.81% | (m) | Reported |
| 2023-03-31 | $48.18M | $317.65M | $7.99M | (m) | $17.21M | 15.17% | 2.52% | (m) | Reported |
| 2022-12-31 | $41.43M | $331.34M | $7.35M | (m) | $15.79M | 12.50% | 2.22% | (m) | Reported |
| 2022-09-30 | $31.49M | $373.22M | $6.58M | (m) | $16.60M | 8.44% | 1.76% | (m) | Reported |
| 2022-06-30 | $20.21M | $403.82M | $3.40M | $359.36M | $16.30M | 5.00% | 0.84% | 22.05× | Reported |
| 2022-03-31 | $6.37M | $396.41M | $2.52M | $373.35M | $17.39M | 1.61% | 0.64% | 21.47× | Reported |
| 2021-12-31 | $576.00K | $391.87M | $2.02M | $375.10M | $19.07M | 0.15% | 0.51% | 19.67× | Reported |
| 2021-09-30 | $755.00K | $374.66M | $1.91M | $355.36M | $18.88M | 0.20% | 0.51% | 18.82× | Reported |
| 2021-06-30 | $1.32M | $365.49M | $1.81M | $345.24M | $18.69M | 0.36% | 0.49% | 18.47× | Reported |
| 2021-03-31 | $1.84M | $343.63M | $1.71M | $324.49M | $18.51M | 0.53% | 0.50% | 17.53× | Reported |
| 2020-12-31 | $1.79M | $336.79M | $1.70M | $321.12M | $18.33M | 0.53% | 0.50% | 17.52× | Reported |
| 2020-09-30 | $1.57M | $322.29M | $1.74M | $309.98M | $18.37M | 0.49% | 0.54% | 16.87× | Reported |
| 2020-06-30 | $559.00K | $299.35M | $1.79M | $286.34M | $18.46M | 0.19% | 0.60% | 15.51× | Reported |
| 2020-03-31 | (m) | $284.51M | $1.89M | $270.31M | $18.56M | (m) | 0.66% | 14.56× | Reported |
| 2019-12-31 | $0.00 | $261.02M | $2.06M | $246.36M | $18.66M | 0.00% | 0.79% | 13.20× | Reported |
| 2019-09-30 | (m) | $264.90M | $2.05M | $249.94M | $18.55M | (m) | 0.78% | 13.47× | Reported |
| 2019-06-30 | (m) | $260.83M | $691.00K | $246.81M | $19.10M | (m) | 0.26% | 12.92× | Reported |
| 2019-03-31 | (m) | $263.81M | $1.67M | $249.72M | $20.91M | (m) | 0.63% | 11.94× | Reported |
| 2018-12-31 | $0.00 | $261.00M | $3.23M | $238.25M | $23.95M | 0.00% | 1.24% | 9.95× | Reported |
| 2018-09-30 | $342.00K | $250.67M | $5.17M | $227.44M | $27.73M | 0.14% | 2.06% | 8.20× | Reported |
| 2018-06-30 | $653.00K | $237.63M | $8.52M | $209.80M | $32.75M | 0.27% | 3.59% | 6.41× | Reported |
| 2018-03-31 | $1.00M | $229.10M | $9.49M | $194.96M | $38.48M | 0.44% | 4.14% | 5.07× | Reported |
| 2017-12-31 | $1.35M | $217.22M | $9.83M | $183.60M | $43.60M | 0.62% | 4.53% | 4.21× | Reported |
| 2017-09-30 | $1.36M | $191.31M | $9.28M | $154.86M | $48.25M | 0.71% | 4.85% | 3.21× | Reported |
| 2017-06-30 | $1.33M | $175.97M | $8.53M | $142.75M | $51.09M | 0.76% | 4.85% | 2.79× | Reported |
| 2017-03-31 | $1.35M | $149.88M | $8.94M | $120.80M | $52.04M | 0.90% | 5.96% | 2.32× | Reported |
| 2016-12-31 | $1.39M | $133.57M | $8.30M | $108.99M | $52.42M | 1.04% | 6.21% | 2.08× | Reported |
| 2016-09-30 | $1.77M | $112.79M | $8.07M | $88.62M | $52.46M | 1.57% | 7.16% | 1.69× | Reported |
| 2016-06-30 | $2.03M | $93.05M | $7.82M | $69.14M | $52.42M | 2.18% | 8.41% | 1.32× | Reported |
| 2016-03-31 | $2.30M | $71.23M | $6.80M | $48.37M | $52.25M | 3.23% | 9.55% | 0.93× | Reported |
| 2015-12-31 | $2.62M | $53.95M | $6.87M | $31.58M | $51.80M | 4.85% | 12.74% | 0.61× | Reported |
| 2015-09-30 | $2.67M | $38.39M | $6.60M | $14.42M | $51.32M | 6.96% | 17.19% | 0.28× | Reported |
| 2015-06-30 | $4.04M | $25.83M | $9.86M | $-3.56M | $50.61M | 15.63% | 38.19% | -0.07× | Reported |
| 2015-03-31 | $5.52M | $16.11M | $15.79M | $-18.46M | $47.95M | 34.29% | 98.01% | -0.38× | Reported |
| 2014-12-31 | $7.50M | $8.43M | $27.39M | $-33.93M | $36.89M | 88.91% | 324.80% | -0.92× | Reported |
| 2014-09-30 | $125.35M | $2.85M | $32.00M | $-181.54M | $26.01M | 4395.06% | 1121.88% | -6.98× | Reported |
| 2014-06-30 | $125.54M | $2.27M | $33.71M | $-179.71M | $15.56M | 5535.36% | 1486.38% | -11.55× | Reported |
| 2014-03-31 | $142.15M | $3.58M | $33.13M | $-201.72M | $8.26M | 3971.84% | 925.59% | -24.43× | Reported |
| 2013-12-31 | $125.18M | $4.76M | $25.69M | $-168.86M | $9.35M | 2630.96% | 539.87% | -18.06× | Reported |
| 2013-09-30 | $119.67M | (m) | $25.44M | $-150.39M | $9.16M | (m) | (m) | -16.41× | Reported |
| 2013-06-30 | $113.30M | (m) | $24.83M | $-138.50M | $8.76M | (m) | (m) | -15.81× | Reported |
| 2013-03-31 | $111.11M | (m) | $23.64M | $-132.43M | $7.24M | (m) | (m) | -18.30× | Reported |
| 2012-12-31 | $117.90M | $135.76M | $23.78M | $-13.00M | $6.00M | 86.84% | 17.52% | -2.17× | Reported |
| 2012-09-30 | $122.25M | $135.32M | $24.25M | $-18.59M | $6.01M | 90.34% | 17.92% | -3.10× | Reported |
| 2012-06-30 | $123.06M | $140.32M | $26.00M | $-14.45M | $6.01M | 87.70% | 18.53% | -2.40× | Reported |
| 2012-03-31 | $116.31M | $145.28M | $25.61M | $-2.40M | $6.01M | 80.06% | 17.63% | -0.40× | Reported |
| 2011-12-31 | $103.57M | $24.51M | $24.92M | $-109.74M | $6.02M | 422.52% | 101.65% | -18.22× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $75.07M | $24.22M | $19.01M | $-78.32M | $6.04M | 309.91% | 78.48% | -12.96× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $77.52M | $24.37M | $20.00M | $-81.36M | $6.05M | 318.06% | 82.05% | -13.44× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |